Compare EHC & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EHC | TWST |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 9.2B |
| IPO Year | 1994 | 2018 |
| Metric | EHC | TWST |
|---|---|---|
| Price | $122.00 | $137.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $143.29 | $46.88 |
| AVG Volume (30 Days) | 739.5K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | 24.22 | ★ 63.89 |
| EPS | ★ 3.47 | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | $9.33 | $18.91 |
| Revenue Next Year | $8.14 | $15.07 |
| P/E Ratio | $35.07 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $92.77 | $23.30 |
| 52 Week High | $127.99 | $155.44 |
| Indicator | EHC | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 56.62 |
| Support Level | $118.77 | $38.64 |
| Resistance Level | $127.50 | $155.44 |
| Average True Range (ATR) | 2.33 | 8.92 |
| MACD | -0.30 | -2.45 |
| Stochastic Oscillator | 68.64 | 42.13 |
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.